Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to September 2004

How Humans Died Last Century

September 2004

By William Faloon

LE Magazine September 2004

How Humans Died Last Century

Challenging the Pessimists
The human genome has been mapped. Stem cell therapies are proving effective. The molecular mechanisms that cancer cells use to escape regulatory control have been identified. The underlying cause of vascular disease in aging humans (endothelial dysfunction) has been validated.13-29 The origin of most age-related diseases (chronic inflammation) has been recognized.30-43 Scientists can now measure the gene-expression effects of potential anti-aging agents in a matter of months.44

Historians later this century will look back at our generation and wonder why doctors did not take advantage of all the wonderful tools at their disposal to eradicate human suffering and premature death.

In 1929, Dr. Alexander Flem-ing’s discovery of penicillin was published in the British Journal of Experimental Pathology. Yet well into the 1940s, humans were still dying of bacterial infections that were curable by penicillin.45

The greatest challenge in battling the bureaucrats and medical establishment is countering their absurd notion that aging will never be controllable. All one has to do, however, is look back 100 years and see how people used to die. In 1900, there was little basis to believe that most lethal bacterial diseases would be eradicated in less than 50 years.


















Reference: National Vital Statistics Report, March 21, 2002.

Right now, an abundance of knowledge reveals that it is only a matter of time before aging becomes a horrifying relic of the past. As long as the majority of people believe this will never happen, the resources committed to discovering a cure for aging will be limited.

When genomic engineering is perfected, not only will it become possible to stop aging, but we may even be able to reverse it. It is difficult to imagine a nobler objective for humankind than making old people young again.

What Must Be Done Today
We cannot allow our generation to die out when an abundance of scientific knowledge indicates that therapies to prevent needless death already exist. Bureaucratic roadblocks must be torn down. Physician apathy must be transformed into a competitive arena where doctors who discover new ways of saving lives are rewarded financially without encountering government interference. Today’s broken health care system can be redressed only in a free-market environment liberated from the regulatory strangulation that is stifling innovation.

Unfortunately, regulators are seeking greater control over what people are allowed to put into their own bodies, over what companies are allowed to sell, and how individual doctors run their own practices. Those with novel solutions for today’s causes of death first have to contend with the FDA and other bureaucracies before they have any hope of making a new therapy available to the masses.


In Mississippi, typhoid fever, diphtheria, malaria, smallpox, and pellagra caused 2,440 deaths in 1930 and 1931. By contrast, in 1959 and 1960, only 16 deaths were reported from these diseases in the state of Mississippi.6

The Life Extension Foundation was established in 1980 as a nonprofit organization dedicated to funding scientific research and educating the public about staying alive. Regrettably, our efforts increasingly are being hindered by regulations that have caused those with creative medical concepts to fear criminal prosecution. This chilling effect results in attorneys being the first ones called when a significant scientific advance is made. The concern is that the government could initiate actions that would economically destroy years of dedicated work, or even put the inventor in jail. The advice of attorneys is to go “slow” or not pursue the discovery at all.

The problem is that we are aging quickly and it will take a Herculean effort to bring together the various scientific disciplines needed to gain control over aging in our lifetimes. Avant-garde scientists are impeded because of antiquated laws that require expensive and time-consuming governmental “approvals” just to test new therapies. These laws must be abolished!

For longer life,

William Faloon


1. Control of infectious diseases. MMWR Morb Mortal Wkly Rep. 1999 Jul 30;48(29):621-9.

2. Available at: Accessed April 29, 2004.

3. Available at: Accessed April 29, 2004.

4. Kolata G. Model shows how medical changes let population surge. New York Times. January 7, 1997.

5. American Cancer Society. Annual report to the nation on the status of cancer, 1975- 2001. Available at: Accessed June 3, 2004.

6. Available at: Accessed April 29, 2004.

7. Available at: Accessed April 29, 2004.

8. Available at Accessed April 29, 2004.

9. Available at: Accessed April 29, 2004.

10. Available at Accessed May 15, 2004.

11. Available at: Accessed April 29, 2004.

12. Available at: Accessed April 29, 2004.

13. Kirby M, Jackson G, Betteridge J, Friedili K. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract. 2001 Nov;55(9):614-8.

14. Rajagopalan S, Han Z, Supiano M, Brook R, Pitt B. Prospective randomized evaluation of losartan in endothelial dysfunction of the aged—the PREVAILED Study. JACC. 2001 Feb;37:274A.

15. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001 Nov 27;104(22):2673-8.

16. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994 Aug;24(2):471-6.

17. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 1999 Sep 14;100(11):1161-8.

18. Küng CF, Lüscher TF. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension. 1995 Feb;25(2):194-00.

19. Taddei S, Galetta F, Virdis A, et al. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. Circulation. 2000 Jun 27;101(25):2896-901.

20. Landmesser U, Harrison DG. Oxidant stress as a marker for cardiovascular events. Ox marks the spot. Circulation. 2001 Nov 27;104(22):2638-40.

21. Schram MT, Chaturvedi N, Schalkwisk C, et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2003 July;26(7):2165- 73.

22. Matz RL. Andriantsitohaina R. Age-related endothelial dysfunction: potential implications for pharmacotherapy. Drugs Aging. 2003;20(7):527-50.

23. Pacher P, Mabley JG, Soriano FG, Liaudet L, Szabo C. Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Int J Mol Med. 2002 Jun;9(6):659-64.

24. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol. 1999 Jan;31(1):23-37.

25. Taddei S, Virdis A, Ghiadoni L, et al. Menopause is associated with endothelial dysfunction in women. Hypertension. 1996 Oct;28(4):576-82.

26. Luscher TF, Tanner FC, Tschudi MR, Noll G. Endothelial dysfunction in coronary artery disease. Annu Rev Med. 1993;44:395- 18.

27. Taddei S, Virdis A, Mattei P, et al. Hypertension causes premature aging of endothelial function in humans. Hypertension. 1997 Mar;29(3):736-43.

28. Murakami T, Mizuno S. Intrinsic and extrinsic nitric oxide provides better and worse prognosis respectively for coronary artery disease. Circulation. 2002 Nov 5;106(19 Suppl II).

29. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995;57:791-04.

30. Ward PA. Cytokines, inflammation, and autoimmune diseases. Hosp Pract. 1995 May 15;30(5):35-41.

31. McCarty MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, dia- betes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pen- toxifylline. Med. Hypotheses. 1999 May;52(5):465-77.

32. Brod SA. Unregulated inflammation shortens human functional longevity. Inflamm Res. 2000 Nov;49(11):561-70.

33. Willard LB, Hauss-Wegrzyniak B, Wenk GL. Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats. Neuroscience. 1999 Jan; 88(1):193- 200.

34. Hogan SP, Mishra A, Brandt EB, et al. A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat. Immunol. 2001 Apr;2(4):353-60.

35. Van der Meide PH, Schellekens H. Cytokines and the immune response. Biotherapy. 1996;8(3-4):243-9.

36. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry. 1999 Jul;4(4): 317-27.

37. Brouqui P, Dumler JS, Raoult D. Immunohistologic demonstration of Coxiella burnetii in the valves of patients with Q fever endocarditis. Am J Med. 1994 Nov;97(5):451-8.

38. Devaux B, Scholz D, Hirche A, Klovekorn WP, Schaper J. Upregulation of cell adhe- sion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J. 1997 Mar;18(3):470-9.

39. De Keyser F, Elewaut D, De Vos M, et al. Bowel inflammation and the spondy- loarthropathies. Rheum Dis Clin North Am. 1998 Nov;24(4):785-813.

40. Invitti C. Obesity and low-grade systemic inflammation. Minerva Endocrinol. 2002 Sep;27(3):209-14.

41. Lee H, Liao JJ, Graeler M, Huang MC, Goetzl EJ. Lysophospholipid regulation of mononuclear phagocytes. Biochim Biophys Acta. 2002 May 23;1582(1-3):175-7.

42. Santoro A, Mancini E. Cardiac effects of chronic inflammation in dialysis patients. Nephrol Dial Transplant. 2002;17(Suppl. 8):10-5.

43. Sitzer M, Markus HS, Mendall MA, Liehr R, Knorr U, Steinmetz H. C-reactive protein and carotid intimal medial thickness in a community population. J Cardiovasc Risk. 2002 Apr;9(2):97-103.

44. Lee CK, Klopp RG, Weindruch R, Prolla TA. Gene expression profile of aging and its retardation by caloric restriction. Science. 1999 Aug 27;285(5432):1390-3.

45. Available at: Accessed April 28, 2004.